Inovio Pharmaceuticals, Inc.
INOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 2, 2026 | H.C. Wainwright | Yi Chen | $5.00(+187%) | $1.74 | StreetInsider |
| Aug 13, 2026 | Jefferies | $3.00(+233%) | $0.90 | TheFly | |
| Jun 1, 2026 | H.C. Wainwright | $2.50(+91%) | $1.31 | TheFly | |
| Nov 14, 2025 | Piper Sandler | Edward Tenthoff | $6.00(+202%) | $1.99 | StreetInsider |
| Aug 9, 2024 | RBC Capital | Gregory Renza | $8.00(-8%) | $8.71 | StreetInsider |
| May 14, 2024 | Oppenheimer | Hartaj Singh | $40.00(+249%) | $11.45 | StreetInsider |
| May 13, 2024 | Stephens | Sudan Loganathan | $20.00(+76%) | $11.36 | TheFly |
| Jan 25, 2024 | Oppenheimer | Hartaj Singh | $4.00(-41%) | $6.79 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Jefferies | maintain | Buy | Nov 6, 2026 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Nov 2, 2026 |
| Jefferies | upgrade | Hold →Buy | Aug 13, 2026 |
| Piper Sandler | maintain | Overweight | Aug 3, 2026 |
| HC Wainwright & Co. | maintain | Neutral | Jun 1, 2026 |
| Piper Sandler | maintain | Overweight | Nov 14, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Aug 14, 2025 |
| RBC Capital | maintain | Sector Perform | May 14, 2025 |
| Oppenheimer | maintain | Outperform | May 14, 2025 |
| RBC Capital | maintain | Sector Perform | Mar 19, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 19, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Jan 13, 2025 |
| JMP Securities | maintain | Market Outperform | Jan 10, 2025 |
| Oppenheimer | maintain | Outperform | Nov 18, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Nov 18, 2024 |
| RBC Capital | maintain | Sector Perform | Nov 15, 2024 |
| Oppenheimer | maintain | Outperform | Aug 12, 2024 |
| RBC Capital | maintain | Sector Perform | Aug 9, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Jul 15, 2024 |
| Oppenheimer | maintain | Outperform | Mar 8, 2024 |
| RBC Capital | maintain | Sector Perform | Mar 7, 2024 |
| Oppenheimer | upgrade | Perform →Outperform | Jan 25, 2024 |
| RBC Capital | maintain | Sector Perform →Perform | May 11, 2023 |
| RBC Capital | maintain | Sector Perform | May 10, 2023 |
| RBC Capital | maintain | Sector Perform | Mar 1, 2023 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.07 | $-0.22 | — | $533.3K |
| May 13, 2026 | $-0.28 | $-0.35 | — | $333.3K |
| Mar 12, 2026 | $0.06 | $-0.37 | — | $333.3K |
| Nov 10, 2025 | $-0.87 | $-0.42 | — | $10.0K |
| Aug 12, 2025 | $-0.61 | $-0.63 | — | $10.0K |
| May 13, 2025 | $-0.51 | $-0.74 | $65.3K | $10.0K |
| Mar 18, 2025 | $-0.69 | $-0.87 | $117.0K | $50.0K |
| Nov 14, 2024 | $-0.89 | $-1.20 | — | $30.0K |
News
PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 58,747,235 shares of its common stock at a public offering price of $1.05 per share of common stock and pre-funded warrants to purchase 12,681,337 shares of common s…
PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Inovio Pharmaceuticals receives FDA Accelerated Approval for VOCERYQ [INO-3107] in recurrent respiratory papillomatosis, prompting a rating upgrade from "Hold" to "Buy." VOCERYQ is the first FDA-approved DNA medicine, highlighting the company's platform and potential for future DNA-based immunotherapy approvals and pipeline expansion. INO faces competition from Precigen's PAPZIMEOS but offers potential advantages in safety, dosing convenience, and injection burden.
Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) all drawing elevated volume.
PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its third quarter 2026 financial results will be released after the market close on November 10, 2026.
PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences: Soft Bones Third International Scientific Meeting on Hypophosphatasia (New York) Presentation: Rare Disease Protein Replacement Therapeutics: The Transformational Potential…
Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP Transcript
Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, formerly known as INO-3107, as a nonsurgical treatment intended to reduce the frequency of surgeries in adults with recurrent respiratory papillomatosis, or RRP.
Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) rose sharply in pre-market trading after the company disclosed that the FDA has granted accelerated approval for Voceryq for the treatment of adults with recurrent respiratory papillomatosis.
INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgery VOCERYQ™ is a plasmid DNA-based immunotherapy that targets the root cause of RRP: HPV-6 and HPV-11 INOVIO expects to make VOCERYQ available to order and ship in approximately 60 days, with full commercial launch in the first quarter of 2027 VOCERYQ represents the first U.S. FDA approved DNA medicine, validating INOVIO's novel platform …
PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI, Inc. ("VGXI") and GeneOne Life Science, Inc. ("GeneOne") in the case captioned INOVIO Pharmaceu…
Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Inovio Pharmaceuticals (NASDAQ: INO - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation. Earnings and Valuation This table compares Pyxis
Tap four stocks with increasing P/E ratios to try out an out-of-the-box investment approach.
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Inovio Pharmaceuticals NASDAQ: INO said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.
Inovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.
Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Tap these five stocks - CURI, INO, GDS, NMG and CCOI - with increasing P/E ratios to try out an out-of-the-box approach.
PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Cantor Global Healthcare Conference (New York) Date: Wednesday, September 9 Fireside Chat: 3:20 PM ET Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenP…
Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration has completed several key steps in its review of the company's biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues preparations for a potential commercial launch.